Exclusive Online Content
Servier and X-Chem, Inc. recently announced a partnership to identify and develop novel small molecules for the treatment of….
Kite, a Gilead Company, and Oxford BioTherapeutics Ltd. recently announced the companies have entered into a research collaboration to evaluate five novel targets for a….
Argenx SE and Zai Lab Limited recently announced an exclusive license agreement for the development and commercialization of efgartigimod in Greater China, including….
ViGeneron GmbH recently announced a global collaboration and licensing agreement with Biogen Inc. to develop and commercialize gene therapy products based on adeno-associated virus (AAV) vectors to treat….
Radius Health, Inc. recently announced it has entered into definitive agreements with Endo Ventures Limited, a subsidiary of Endo International plc to register, commercialize, and distribute abaloparatide on an exclusive basis in….
University of Calgary Joins the Phase 2 Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients
Arch Biopartners Inc. RECENTLY announced the University of Calgary Cumming School of Medicine has joined the Phase 2 trial of its lead drug LSALT peptide (Metablok), targeting the prevention….
Ajinomoto Bio-Pharma Services and Revance Therapeutics, Inc. recently announced a strategic commercial manufacturing agreement for the supply of DaxibotulinumtoxinA for….
Vectura Group plc recently announced its partner Hikma Pharmaceuticals has launched its generic version of GlaxoSmithKline’s Advair Diskus (fluticasone propionate and salmeterol inhalation powder)….
Aurinia Pharmaceuticals Inc. and Lonza recently announced they have expanded their exclusive manufacturing relationship. The parties entered into a collaborative agreement to build….
Gattefossé is investing 30 million euros in its industrial operations and announced the construction of a brand new manufacturing plant in Lufkin, TX. This asset will produce lipid-based….
EXCLUSIVE ONLINE CONTENT
Credence MedSystems recently announced that Novartis has made a strategic investment in the company. The investment will advance ongoing development and scaling of Credence’s innovative drug delivery systems….
Nexelis, a portfolio company of Ampersand Capital Partners, and a leading provider of advanced assay development and laboratory testing services in the infectious, oncologic, and metabolic diseases fields, has signed an asset purchase agreement with GSK to….
ViGeneron Announces Research Collaboration With Daiichi Sankyo to Evaluate Novel Ophthalmic Gene Therapy
ViGeneron GmbH recently announced a research collaboration to utilize its novel engineered adeno-associated virus (vgAAV) vectors with Daiichi Sankyo Company, Limited for delivering….
Molecular Templates Announces FDA Acceptance of IND Application for a PD-L1-Targeted Engineered Toxin Body Enabled With Proprietary Antigen Seeding Technology
Molecular Templates, Inc. recently announced the US FDA has accepted its Investigational New Drug (IND) application for MT-6402, a next-generation ETB targeting PD-L1 that is enabled with….
Clene Inc. recently announced its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, was issued a Notice of Allowance from the US Patent and Trademark Office (USPTO) for its invention for….